Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa - 15/08/19
Abstract |
Background |
Few data exist to guide infliximab dosing in hidradenitis suppurativa (HS).
Objectives |
To determine optimal infliximab dosing for patients with HS based on treatment response and achievement of stable dosing.
Methods |
Retrospective cohort study of 52 patients with HS treated with infliximab. Primary outcome was achievement of stable dosing regimen for at least 8 weeks. Secondary outcomes were time to discontinuation, time to titration, changes to inflammatory markers, and clinical response.
Results |
Thirty-five patients (67%) achieved stable dosing, most at a schedule of 10 mg/kg every 6 or 8 weeks. At 1 year from initiation, most patients (64%) required dose escalation. Patients tolerated infliximab well and achieved significant improvements in abscess and nodule count, draining sinuses, and erythrocyte sedimentation rate.
Limitations |
Retrospective nature and lack of HS clinical response data for many patients.
Conclusions |
Infliximab 10 mg/kg every 6 or 8 weeks may be a reasonable starting dosage for most patients.
Le texte complet de cet article est disponible en PDF.Key words : clinical research, drug response, general dermatology, hidradenitis, infliximab, medical dermatology
Abbreviations used : AN, CRP, ESR, HiSCR, HS, RCT
Plan
Funding sources: None. |
|
Disclosure: Dr Sayed is a speaker, co-investigator, and advisory board member for AbbVie, Inc; a speaker and co-investigator for Novartis; an investigator and scientific advisory board member for InflaRx; and an investigator for UCB. Oskardmay and Miles have no conflicts of interest to declare. |
|
Reprints not available from the authors. |
Vol 81 - N° 3
P. 702-708 - septembre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?